SCHEMBL1679941

SCHEMBL1679941

CCOC(=O)c1cc(Oc2ccc(OC(F)(F)F)cc2)c(C)cc1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP10 Q14694 1/20 0.44
ALDH1A1 P00352 6/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
POLB P06746 3/20 0.43
LMNA P02545 3/20 0.43
HPGD P15428 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MITF O75030 2/20 0.43
GALR2 O43603 1/20 0.43
HSP90AA1 P07900 1/20 0.43
XBP1 P17861 1/20 0.43
CCR6 P51684 1/20 0.43
THRB P10828 1/20 0.41
KMT2A Q03164 4/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1679937 0.88 TDP1 (0.50) USP10ALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL1679925 0.87 MAPT (0.43) ALDH1A1SMN1; SMN2NPSR1KMT2AMAPK1
SCHEMBL1679874 0.86 MAPT (0.40) ALDH1A1SMN1; SMN2HPGDNPSR1MAPK1
SCHEMBL1679943 0.85 KMT2A (0.40) ALDH1A1SMN1; SMN2LMNAHPGDNPSR1
SCHEMBL1679929 0.81 KMT2A (0.44) ALDH1A1SMN1; SMN2POLBLMNAHPGD
SCHEMBL16527981 0.80 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2POLBLMNAHPGD
SCHEMBL27249063 0.79 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2POLBLMNAHPGD
SCHEMBL28694262 0.78 SLC6A4 (0.39) ALDH1A1SMN1; SMN2LMNAHPGDNPSR1
SCHEMBL1679958 0.78 TDP1 (0.49) USP10ALDH1A1SMN1; SMN2POLBHPGD
SCHEMBL1780310 0.78 TDP1 (0.57) ALDH1A1SMN1; SMN2POLBLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305649-B1 METHOD FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREOF NIPPON KAYAKU KK (JP) 2013-04-24 EP disclosed
US-8367833-B2 Process for producing 6-aryloxyquinoline derivative and intermediate therefor NIPPON KAYAKU CO., LTD. (JP) 2013-02-05 US disclosed
US-20110118468-A1 PROCESS FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREFOR MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) 2011-05-19 US disclosed
EP-2305649-A1 METHOD FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREOF Nippon Kayaku Co., Ltd. (JP) 2011-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118468-A1 PROCESS FOR PRODUCING 6-ARYLOXYQUINOLINE DERIVATIVE AND INTERMEDIATE THEREFOR FAR1, CYP4F11, WEE2 USP10 3067/4885ALDH1A1 335/4885SMN1; SMN2 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.